TESTING OF ANTIPROGESTATIONAL/POSTCOITAL AGENTS

拟议的研究是一项为期36个月的综合性研究， 生物测试计划旨在开发新的 干扰孕酮受体的抗孕药 利用率，口服比米非司酮更有效十倍 并且具有最小的激素和拮抗活性， 抗孕药拟议的研究可能会导致开发 米非司酮的新衍生物， 具有较少或不具有抗糖皮质激素的抗孕效力 活性，并具有更好的药代动力学和溶解性特征， 因此，提供了一种性交后紧急治疗，以及一种新的，高度 安全有效的避孕药。

The proposed research is a comprehensive, 36-month, synthetic and biological testing program aimed at the development of novel antiprogestational agents that will interfere with progesterone receptor utilization, and that are orally tenfold more potent than mifepristone and have minimal hormonal and antagonistic activity other than antiprogestational. The proposed research may lead to the development of new derivatives of mifepristone that show significantly improved oral antiprogestational potency with less or without antiglucocorticoid activity, and have better pharmacokinetic and solubility characteristics, thus-providing a postcoital emergency therapy as well as a new, highly effective, and safe contraceptive agent.